Arrhythmias & EP
News from the FDA/CDC
FDA issues public health warning recommending against cesium salt usage
Cesium salts are sometimes advertised as an alternative treatment for cancer.
Conference Coverage
Heart rhythm data from wearables confounds EP practice
NATIONAL HARBOR, MD. – Cardiac electrophysiologists increasingly see patients who’ve received arrhythmia alerts from wearable devices.
News
Expanded indication for leadless pacemaker triples eligible patients
Conference Coverage
Vigilance safely keeps AFib patients off anticoagulants post ablation
NATIONAL HARBOR, MD. – One U.S. center uses frequent monitoring to allow selected AFib patients to safely stop anticoagulation after catheter...
Conference Coverage
AFib link with titin mutations warrants selected genetic testing
Evidence strongly links loss-of-function mutations in the titin gene with AFib, and patients are now seeking genetic testing.
From the Journals
Cardiovascular risks associated with cannabis use
Review authors suggest cardiovascular patients may benefit from cannabis screening and testing.
Guidelines
HRS urges consumers to direct questions about wearables’ data to clinicians
News
FDA okays first generics for Eliquis
“These approvals mark the first generic approvals of a direct oral anticoagulant.”
Conference Coverage
Hydroxychloroquine prevents congenital heart block recurrence in anti-Ro pregnancies
ATLANTA – Women taking the drug experienced more than a 50% drop in the rate of congenital heart block in comparison to the historical rate.
News
FDA panel rejects vernakalant bid for AFib cardioversion indication
Eleven years after the first attempt of the antiarrhythmic agent, the FDA panel voted resoundingly against approval.
Conference Coverage
Genetic test stratified AFib patients with low CHA2DS2-VASc scores
A 32-locus genetic test classified AFib patients with low CHA2DS2-VASc scores into high– and low–stroke-risk subgroups.